[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201892383A1 - Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина - Google Patents

Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина

Info

Publication number
EA201892383A1
EA201892383A1 EA201892383A EA201892383A EA201892383A1 EA 201892383 A1 EA201892383 A1 EA 201892383A1 EA 201892383 A EA201892383 A EA 201892383A EA 201892383 A EA201892383 A EA 201892383A EA 201892383 A1 EA201892383 A1 EA 201892383A1
Authority
EA
Eurasian Patent Office
Prior art keywords
analogue
oxyntomodulin
diabetes
treatment
composition
Prior art date
Application number
EA201892383A
Other languages
English (en)
Other versions
EA037956B1 (ru
Inventor
Чин Сун Ким
Дэ Джин Ким
Сан Хюн Ли
Сун Юб Чун
Се Чан Квон
Original Assignee
Ханми Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ханми Фарм. Ко., Лтд. filed Critical Ханми Фарм. Ко., Лтд.
Publication of EA201892383A1 publication Critical patent/EA201892383A1/ru
Publication of EA037956B1 publication Critical patent/EA037956B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к композиции для предупреждения или лечения диабета, диажирения или осложнений диабета, содержащей аналог оксинтомодулина в качестве активного ингредиента. Изобретение также относится к способу лечения диабета, диажирения или осложнений диабета, включающему введение субъекту фармацевтически эффективного количества аналога оксинтомодулина. Аналог оксинтомодулина обладает высокой способностью к активации рецептора GLP-1 (глюкагоноподобного пептида-1) и рецептора глюкагона по сравнению с нативным оксинтомодулином. Аналог оксинтомодулина индуцирует развитие бета-клеток и повышает секрецию инсулина, снижая в результате этого уровни глюкозы в крови, которые были повышены вследствие высококалорийного рациона с высоким содержанием жира. Аналог оксинтомодулина индуцирует снижение массы тела и уменьшение приема пищи с повышением чувствительности к инсулину и дает возможность поддержания уровней глюкозы в крови, которые не контролируются вследствие инсулинорезистентности, на нормальных уровнях. Следовательно, аналог оксинтомодулина можно эффективно применять для предупреждения или лечения диабета и родственных заболеваний.
EA201892383A 2012-11-06 2013-11-06 Композиция для лечения диабета или диажирения, содержащая конъюгат аналога оксинтомодулина EA037956B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120124724A KR101993393B1 (ko) 2012-11-06 2012-11-06 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물

Publications (2)

Publication Number Publication Date
EA201892383A1 true EA201892383A1 (ru) 2019-03-29
EA037956B1 EA037956B1 (ru) 2021-06-15

Family

ID=50684885

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201892383A EA037956B1 (ru) 2012-11-06 2013-11-06 Композиция для лечения диабета или диажирения, содержащая конъюгат аналога оксинтомодулина
EA201590759A EA031928B1 (ru) 2012-11-06 2013-11-06 Композиция для лечения диабета или диажирения, содержащая конъюгат аналога оксинтомодулина

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201590759A EA031928B1 (ru) 2012-11-06 2013-11-06 Композиция для лечения диабета или диажирения, содержащая конъюгат аналога оксинтомодулина

Country Status (30)

Country Link
US (2) US20150299282A1 (ru)
EP (2) EP2916860B1 (ru)
JP (4) JP6363613B2 (ru)
KR (1) KR101993393B1 (ru)
CN (1) CN104918632B (ru)
AR (2) AR093386A1 (ru)
AU (3) AU2013342324B2 (ru)
BR (3) BR112015010203B1 (ru)
CA (1) CA2890329C (ru)
CL (1) CL2015001207A1 (ru)
DK (1) DK2916860T3 (ru)
EA (2) EA037956B1 (ru)
ES (1) ES2802099T3 (ru)
HK (1) HK1211856A1 (ru)
HR (1) HRP20200925T1 (ru)
HU (1) HUE049240T2 (ru)
IL (2) IL238631B (ru)
LT (1) LT2916860T (ru)
MX (1) MX360335B (ru)
MY (1) MY173828A (ru)
NZ (2) NZ738835A (ru)
PE (1) PE20151420A1 (ru)
PH (2) PH12018501424A1 (ru)
PL (1) PL2916860T3 (ru)
PT (1) PT2916860T (ru)
SG (3) SG10202110636WA (ru)
TW (4) TWI741218B (ru)
UA (1) UA117570C2 (ru)
WO (1) WO2014073845A1 (ru)
ZA (1) ZA201503999B (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2718318T (lt) 2011-06-10 2018-10-25 Hanmi Science Co., Ltd. Nauji oksintomodulino dariniai ir farmacinė kompozicija, apimanti šiuos darinius, nutukimo gydymui
PT2721062T (pt) 2011-06-17 2019-02-12 Hanmi Science Co Ltd Conjugado que compreende oxintomodulina e um fragmento de imunoglobulina e utilização do mesmo
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
NZ739063A (en) 2012-11-06 2019-11-29 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
EP2934569A1 (en) 2012-12-21 2015-10-28 Sanofi Exendin-4 derivatives
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
MX2016012788A (es) * 2014-03-31 2016-12-12 Hanmi Pharm Ind Co Ltd Procedimiento para mejorar la solubilidad de proteinas y peptidos usando un enlace del fragmento fc de inmunoglobulina.
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
TW201639878A (zh) * 2014-12-30 2016-11-16 韓美藥品股份有限公司 具有改善之安定性的升糖素衍生物
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2017003191A1 (en) 2015-06-30 2017-01-05 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
EP3359191A4 (en) 2015-10-05 2019-05-29 Merck Sharp & Dohme Corp. ANTIBODY-PEPTIDE CONJUGATES HAVING AGONIST ACTIVITY AT GLUCAGON AND PEPTIDE-1 RECEPTORS SIMILAR TO GLUCAGON
EP3359194A4 (en) 2015-10-06 2019-04-24 Merck Sharp & Dohme Corp. ANTIBODY-ACTIVE CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS
TWI800478B (zh) 2015-12-31 2023-05-01 南韓商韓美藥品股份有限公司 三重升糖素/glp-1/gip受體促效劑
EP3407916B1 (en) 2016-01-29 2023-12-20 Merck Sharp & Dohme LLC Phosphonate linkers and their use to facilitate cellular retention of compounds
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
AU2017289014B2 (en) * 2016-06-29 2019-12-05 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
KR102698929B1 (ko) 2016-09-23 2024-08-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도
CN108299554B (zh) * 2017-01-13 2021-05-25 博瑞生物医药（苏州）股份有限公司 胃泌酸调节素类似物
AU2018239037B2 (en) 2017-03-23 2022-05-26 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
CN106986924A (zh) * 2017-03-23 2017-07-28 中国药科大学 胃泌酸调节素（oxm）类似物及其应用
EP3689914A4 (en) * 2017-09-29 2021-08-25 Hanmi Pharm. Co., Ltd. PERSISTENT PROTEIN CONJUGATE WITH IMPROVED EFFICIENCY
WO2019171352A2 (en) * 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
WO2020017919A1 (ko) * 2018-07-19 2020-01-23 한미정밀화학주식회사 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
US20210317178A1 (en) * 2018-07-19 2021-10-14 D&D Pharmatech Inc. Pharmaceutical composition comprising polypeptide
US11929171B2 (en) 2018-10-18 2024-03-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for evaluation and treatment of glycemic dysregulation and atherosclerotic cardiovascular disease and applications thereof
US20200262887A1 (en) 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
WO2020128967A2 (en) * 2018-12-19 2020-06-25 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity
WO2020167010A1 (ko) * 2019-02-15 2020-08-20 한미정밀화학주식회사 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
KR102094103B1 (ko) * 2019-05-08 2020-03-27 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 당뇨병 예방 또는 치료용 약학 조성물
WO2022104394A1 (en) * 2020-11-16 2022-05-19 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for diagnostic assessment and treatment of insulin resistance and hyperglycemia

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
EP1060746A4 (en) 1998-03-06 2002-06-19 Chugai Pharmaceutical Co Ltd PROTEIN-FREE PREPARATIONS
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
CN1723220A (zh) * 2003-11-13 2006-01-18 韩美药品工业株式会社 含有免疫球蛋白fc区作为载体的药物组合物
AU2005311099B2 (en) 2004-12-02 2012-02-02 Domantis Limited Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
EP2390264A1 (en) 2005-02-11 2011-11-30 Amylin Pharmaceuticals Inc. GIP analog and hybrid polypeptides with selectable propperties
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
ATE553124T1 (de) 2005-06-13 2012-04-15 Imp Innovations Ltd Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
CA2638800A1 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
AU2007258609B2 (en) 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
GEP20135944B (en) 2007-02-15 2013-10-25 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
NZ582480A (en) 2007-07-10 2011-03-31 Lilly Co Eli Glp-1-fc fusion protein formulation
WO2009033739A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2214691B1 (en) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
EA019203B9 (ru) 2008-06-17 2014-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты глюкагонового рецептора/glp-1-рецептора
RU2560254C2 (ru) 2008-06-17 2015-08-20 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ И СТАБИЛЬНОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМИ ЗНАЧЕНИЯМИ Ph
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010033220A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
WO2010070253A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
AR074811A1 (es) 2008-12-19 2011-02-16 Univ Indiana Res & Tech Corp Profarmaco de peptido de la superfamilia de glucagon basados en amida
WO2010096052A1 (en) * 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
MX2011009798A (es) 2009-03-20 2011-12-08 Amgen Inc Inmunoglobulinas portadoras y usos de las mismas.
MY150536A (en) 2009-03-20 2014-01-30 Hanmi Science Co Ltd Method for preparing a site-specific physiologically active polypeptide conjugate
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
PT2454282E (pt) 2009-07-13 2015-06-23 Zealand Pharma As Análogos de glucagão acilados
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
WO2011071957A1 (en) 2009-12-07 2011-06-16 Sea Lane Biotechnologies, Llc Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
WO2011075393A2 (en) * 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
AR079345A1 (es) * 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
AU2011231503C1 (en) 2010-03-26 2016-03-03 Novo Nordisk A/S Novel glucagon analogues
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
KR20130102470A (ko) * 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN101974077A (zh) 2010-09-15 2011-02-16 南京瑞年天平医药科技有限公司 一种新颖的多肽化合物
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
KR101767570B1 (ko) * 2010-10-26 2017-08-14 한미사이언스 주식회사 항 비만 펩타이드의 지속형 결합체
CN102010473A (zh) * 2010-11-10 2011-04-13 曹鹏 重组胃泌酸调节素融合蛋白及其制备和应用
JP2014501762A (ja) 2010-12-22 2014-01-23 マルケイディア バイオテック， インコーポレイテッド Ｇｉｐおよびｇｌｐ−１受容体活性グルカゴン系ペプチドにより代謝障害および肥満を治療するための方法
EP2492749A1 (en) 2011-02-28 2012-08-29 Rohm and Haas Electronic Materials LLC Photoresist compositions and methods of forming photolithographic patterns
KR101161526B1 (ko) 2011-05-16 2012-07-02 숭실대학교산학협력단 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법
LT2718318T (lt) 2011-06-10 2018-10-25 Hanmi Science Co., Ltd. Nauji oksintomodulino dariniai ir farmacinė kompozicija, apimanti šiuos darinius, nutukimo gydymui
PT2721062T (pt) 2011-06-17 2019-02-12 Hanmi Science Co Ltd Conjugado que compreende oxintomodulina e um fragmento de imunoglobulina e utilização do mesmo
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
WO2013157002A1 (en) 2012-04-19 2013-10-24 Prolor Biotech Inc. Long-acting oxyntomodulin variants and methods of producing same
AR091477A1 (es) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
NZ739063A (en) * 2012-11-06 2019-11-29 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
JP6137046B2 (ja) 2014-05-09 2017-05-31 信越化学工業株式会社 単量体、高分子化合物、レジスト材料及びパターン形成方法

Also Published As

Publication number Publication date
LT2916860T (lt) 2020-07-10
IL238631A0 (en) 2015-06-30
DK2916860T3 (da) 2020-06-15
JP7050834B2 (ja) 2022-04-08
BR122019024272B1 (pt) 2021-05-18
ZA201503999B (en) 2016-07-27
TWI754980B (zh) 2022-02-11
EP2916860B1 (en) 2020-03-11
IL238631B (en) 2020-04-30
JP7341263B2 (ja) 2023-09-08
PH12018501424B1 (en) 2019-04-01
EA037956B1 (ru) 2021-06-15
AU2018200138B2 (en) 2019-09-12
MY173828A (en) 2020-02-24
EA031928B1 (ru) 2019-03-29
HRP20200925T1 (hr) 2020-09-18
TWI741218B (zh) 2021-10-01
EP3679944A1 (en) 2020-07-15
NZ748034A (en) 2020-10-30
AU2019275590A1 (en) 2020-01-02
AR126851A2 (es) 2023-11-22
PH12018501424A1 (en) 2019-04-01
PE20151420A1 (es) 2015-09-24
TW202144394A (zh) 2021-12-01
US20150299282A1 (en) 2015-10-22
TWI755341B (zh) 2022-02-11
IL273305B (en) 2021-10-31
BR112015010203A2 (pt) 2017-08-22
NZ738835A (en) 2020-03-27
PH12015501009B1 (en) 2015-07-27
JP2020079301A (ja) 2020-05-28
TW201900206A (zh) 2019-01-01
EA201590759A1 (ru) 2015-12-30
JP6363613B2 (ja) 2018-07-25
KR101993393B1 (ko) 2019-10-01
UA117570C2 (uk) 2018-08-27
BR112015010203B1 (pt) 2021-05-18
JP2022048398A (ja) 2022-03-25
MX360335B (es) 2018-10-29
EP2916860A1 (en) 2015-09-16
MX2015005699A (es) 2016-02-05
ES2802099T3 (es) 2021-01-15
JP6666959B2 (ja) 2020-03-18
US10550168B2 (en) 2020-02-04
EP2916860A4 (en) 2016-06-22
CA2890329C (en) 2024-01-23
AU2018200138A1 (en) 2018-02-01
IL273305A (en) 2020-04-30
JP2015536943A (ja) 2015-12-24
SG10201703732VA (en) 2017-06-29
CN104918632A (zh) 2015-09-16
TW202041528A (zh) 2020-11-16
BR122021003984B1 (pt) 2022-07-12
CN104918632B (zh) 2017-10-31
CL2015001207A1 (es) 2015-07-03
SG10202110636WA (en) 2021-11-29
KR20140058104A (ko) 2014-05-14
AU2019275590B2 (en) 2022-01-20
JP2018162298A (ja) 2018-10-18
AU2013342324A1 (en) 2015-05-28
TWI645856B (zh) 2019-01-01
TW201422232A (zh) 2014-06-16
US20180237490A1 (en) 2018-08-23
HUE049240T2 (hu) 2020-09-28
SG11201503420QA (en) 2015-05-28
BR112015010203A8 (pt) 2019-11-26
NZ708105A (en) 2018-06-29
PL2916860T3 (pl) 2020-11-02
CA2890329A1 (en) 2014-05-15
EP3679944B1 (en) 2022-03-30
AR093386A1 (es) 2015-06-03
PT2916860T (pt) 2020-07-02
WO2014073845A1 (en) 2014-05-15
AU2013342324B2 (en) 2018-02-22
PH12015501009A1 (en) 2015-07-27
HK1211856A1 (en) 2016-06-03

Similar Documents

Publication Publication Date Title
EA201892383A1 (ru) Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина
EA201792203A1 (ru) Фармацевтические композиции для комбинированной терапии
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
EA201190048A1 (ru) Аналоги глюкагона
EA201190054A1 (ru) Аналоги глюкагона
EA201190049A1 (ru) Аналоги глюкагона
EA201190047A1 (ru) Аналоги глюкагона
PH12015500688A1 (en) Exendin-4 derivatives as dual glp1/glucagon agonists
EA201692159A1 (ru) Композиция для лечения диабета, содержащая конъюгат на основе аналога инсулина длительного действия и конъюгат на основе аналога инсулинотропного пептида длительного действия
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
MX2015008077A (es) Derivados de exendina-4 como agonistas dobles de glp1/gip o trigonal de glp1-gip/glucagon.
EA200870575A1 (ru) Композиции и способы лечения застойной сердечной недостаточности
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
MX360304B (es) Composiciones de activador de glucocinasa para el tratamiento de la diabetes.
WO2018169282A3 (ko) Atpif1을 함유하는 당뇨 치료용 약학조성물
Tanaka et al. Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats
RU2019133674A (ru) Лечение сахарного диабета с помощью составов инсулинов длительного действия
WO2011163183A3 (en) Methods for delaying progression of diabetes using salacia oblonga extract
EA201691420A1 (ru) Композиции енолазы 1 (eno1) и их применение
JP2014129405A5 (ru)
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
WO2012154009A3 (ko) 티에노피리미딘 유도체， 이의 약학적으로 허용가능한 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨 관련 질환의 또는 치료용 약학적 조성물
MX2014001855A (es) Nuevo compuesto aislado de quamoclit, y una composicion para la prevencion o el tratamiento de la diabetes que contiene el compuesto como un ingrediente activo.
TH172599A (th) องค์ประกอบสำหรับการบำบัดรักษาโรคเบาหวานหรือโรคเบาหวานในคนอ้วน (diabesity) ที่ประกอบด้วย ออกซินโทโมดูลินอะนาล็อก (Oxyntomodulin Analog)
Yabe [AB3-3]: Does incretin-based therapy increase the risk of pancreatitis or pancreatic cancer? No